HUTCHMED DRC

Yahoo Finance • 5 months ago

HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status

HUTCHMED (China) Limited HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 04, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that the New Drug Application (“NDA”) for tazemeto... Full story

Yahoo Finance • 11 months ago

HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms

HUTCHMED (China) Limited HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that under the 2023 simple renewal mechanis... Full story

Yahoo Finance • last year

HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has completed patient enrollment of a bridging study of tazemetos... Full story

Yahoo Finance • last year

HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Aug. 28, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that the Center for Drug Evaluation of China’s National Medical Pro... Full story

Yahoo Finance • last year

HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China

— Randomized, double-blind, controlled trial met primary endpoint of durable response rate and all secondary endpoints — — Overall safety consistent with sovleplenib known profile — — Plans for regulatory submission underway in China, wh... Full story

Yahoo Finance • last year

HUTCHMED Initiates Phase I Study of its novel SHP2 inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 09, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has initiated a Phase I study in China of HMPL-415, an inve... Full story

Yahoo Finance • 2 years ago

HUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J. , April 17, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that its New Drug Application (“NDA”) for fruquintinib in combina... Full story

Yahoo Finance • 2 years ago

HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer

— NDA supported by data from global Phase III FRESCO-2 study in the U.S., Europe, Japan and Australia along with data from Phase III FRESCO study conducted in China — — FRESCO-2 showed fruquintinib treatment reduced the risk of death by 3... Full story

Yahoo Finance • 2 years ago

HUTCHMED Confirms No Assets Held at Silicon Valley Bank

HUTCHMED (China) Limited HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 13, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM, HKEX:​13) today confirms that it does not have any... Full story

Yahoo Finance • 2 years ago

HUTCHMED Completes Patient Enrollment of ESLIM-01, a Phase III Trial of Sovleplenib in Primary Immune Thrombocytopenia in China

HUTCHMED (China) Limited HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Jan. 03, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that it has completed patient enrollment of... Full story

Yahoo Finance • 2 years ago

HUTCHMED Initiates Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Colorectal Cancer

HUTCHMED (China) Limited — Company plans to complete rolling submission to the U.S. in the first half of 2023, followed by filings in Europe and Japan — — NDA is supported by global Phase III FRESCO-2 study conducted in the U.S., Europe,... Full story

Yahoo Finance • 2 years ago

Prenetics Acquires ACT Genomics, Creating a Leader in Comprehensive Cancer Genetics and Precision Oncology

Prenetics Limited Acquisition to bring germline and somatic testing, cell-free DNA-based (liquid biopsy), and tissue-genomic profiling onto a single platform Cancer genomics testing is now standard practice for cancer care and has shown t... Full story

Yahoo Finance • 2 years ago

HUTCHMED Announces Strategy to Focus on Late-Stage Pipeline Regulatory Approvals

Reprioritization accelerating path to profitability Evaluation of partnership opportunities for select late-stage assets HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HU... Full story

Yahoo Finance • 2 years ago

HUTCHMED Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in Second-Line Gastric Cancer in China

— Results of dual primary endpoint study showed statistically significant and clinically meaningful benefit in progression-free survival, a primary endpoint — — Overall survival, the other primary endpoint, was not statistically significa... Full story

Yahoo Finance • 2 years ago

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 16th and 17th, 2022

Virtual Investor Conferences NEW YORK, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Wednesday, November 16 and Thursday, November 17, featu... Full story

Yahoo Finance • 2 years ago

Inmagene and HUTCHMED Announce First Participant in Global Phase I Trial of IMG-004

HUTCHMED (China) Limited SAN DIEGO and SHANGHAI, China and HONG KONG, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Inmagene Biopharmaceuticals ("Inmagene") and HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) announce today that the... Full story

Yahoo Finance • 2 years ago

HUTCHMED Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer

— Trial met primary endpoint of overall survival and all secondary endpoints — — Overall safety consistent with fruquintinib known profile — — Plans for regulatory submissions underway in the U.S., Europe and Japan — — Results to be sub... Full story

Yahoo Finance • 2 years ago

HUTCHMED Reports 2022 Interim Results and Provides Business Updates

HUTCHMED (China) Limited Oncology/Immunology revenues up 113% to $91.1 million, due to ELUNATE®, SULANDA® and ORPATHYS® growth First presentation of SAVANNAH data showing 52% response rate and 9.6 month duration of response in 2L+ post-T... Full story

Yahoo Finance • 2 years ago

HUTCHMED Highlights First Presentation of Results of the SAVANNAH Global Phase II Trial of Savolitinib plus TAGRISSO® at the 2022 WCLC Annual Meeting

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 12, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces the first presentation of results from the ongoing SAVANNAH global Ph... Full story

Yahoo Finance • 3 years ago

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 10th and 11th, 2022

Virtual Investor Conferences DB DB Logo NEW YORK, May 08, 2022 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Tuesday, May 10 and Wednesday, May 11, featu... Full story